Login

 

Frost & Sullivan: Globalization of Clinical Trials Advances Case for Clinical Trial Management Systems.

HEALTH AND BEAUTY CLOSE-UP-8 June 2008-Frost & Sullivan: Globalization of Clinical Trials Advances Case for Clinical Trial Management Systems(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com

Contract research organizations (CROs) hope to obtain an edge in the highly competitive healthcare

industry by using technology to shorten project times, improve data quality, and thus, differentiate services, reports Frost & Sullivan.

As clinical trials globalize, sponsor companies and CROs increasingly look for tools that will help them simultaneously view, manage and discuss these trials across multiple sites.

New analysis from the consulting company, U.S. Clinical Trial Management Systems Markets, finds that market earned revenues of $237.6 million in 2007 and estimates to grow at a compound annual growth rate of 14.5 percent between 2007 and 2014.

Clinical trial management systems (CTMS) have emerged as the best-suited solution to provide this competitive advantage to CROs. These tools will also enable the CRO to collaborate with clients and contribute key information that enhances data quality.

CTMS employs intelligent applications and access to clean data. This helps users improve overall efficiency and shortens trial timelines, lowering overall cost through better utilization of resources. In addition, the systems use automated data checks to ensure reliability of data, thereby reducing the need for expensive back-end queries and reconciliation.

CTMS has the potential to enable decision making and improve patient safety protection, notes Frost & Sullivan Research Analyst Barath Shankar S. The success of implementing electronic data capture (EDC) solutions is a strong driver for the implementation of CTMS solutions.

CROs are under increased pressure to explain the rapid rise in the number of post-marketing adverse events. This drives them to invest in tools that capture and manage trial data more effectively.

While this trend likely pleases vendors of the highly dynamic CMTS market, participants must also prepare for the eventual maturing of the market. Henceforth, system vendors will increasingly deal directly with CROs, which will be primary decision makers while choosing the vendor.

Additionally, CROs will be conscientious while selecting a CMTS vendor to conduct business with, since sponsors will prefer CROs that function as a one-stop shop and offer integrated solutions for running and managing trials.

Meanwhile, the cost and resource implications for smaller CROs and BioPharma companies in CTMS implementation are significant, notes Shankar. It is important to account for hidden costs while calculating the total cost of deployment and operation of CTMS solutions.

U.S. Clinical Trial Management Systems Markets is part of the Pharmaceutical & Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: global pharmaceutical contract manufacturing markets, global CRO spending trends, and U.S. drug discovery CRO markets.

((Comments on this story may be sent to newsdesk@closeupmedia.com))

((Distributed via M2 Communications Ltd - http://www.m2.com))

T T T
Print icon - email article Email this Article icon - digg  Digg It icon - del.icio.us  del.icio.us

Related Articles

  • etrials Extends 3 Customer Pacts.
    • HEALTH AND BEAUTY CLOSE-UP-25 April 2007-etrials Extends 3 Customer Pacts(C)2007 - CloseUpMedia - newsdesk@closeupmedia.com etrials Worldwide, a provider of eClinical software and services that optimize clinical-trial management and accelerate time-to-market, announced that the company has signed three new contracts with ......
  • WHO launches effort to standardize access to clinical trial registry data.
    • The World Health Organization has launched a major initiative to standardize the way that information on clinical trials is made available to the public. In an attempt to address growing public concerns about the transparency of medical research involving human ......
  • WHO seeks to standardize clinical trial registries.
    • The World Health Organization has launched a major initiative to standardize the way information on clinical trials is made available to the public. In an attempt to address growing public concerns about the transparency of medical research involving human participants, ......
  • WHO moves to standardize clinical trial info.
    • The World Health Organization has launched a major initiative to standardize the way that information on clinical trials is made available to the public. In an attempt to address growing public concerns about the transparency of medical research involving human ......
  • Software Tracks Clinical Trial Data.
    • HARBOR SPRINGS, MICH. -- A new practice-based software package can turn any family physician's office into a clinical trial site, Dr. Lee Green said at the scientific assembly of the Michigan Academy of Family Physicians. Put simply, CLINFOTRACKER is a ......
  • Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, doubleblind, lisinopril-controlled clinical trial.
    • Hibiscus sabdariffa L. (Malvaceae) has been used in different countries as an antihypertensive. Pharmacological work has demonstrated that this effect is probably produced by a diuretic activity and inhibition of the angiotensin-converting enzyme (ACE). Two clinical trials have confirmed the ......
  • ILYPSA COMPLETES PHASE 1 CLINICAL TRIAL OF ILY101.
    • Ilypsa, Inc., Santa Clara, Calif., pioneering next-generation non-absorbed polymeric drugs for renal and metabolic disorders, has completed a Phase 1 clinical trial for ILY101, a novel phosphate binding agent that is being developed for the treatment of hyperphosphatemia, a serious ......
  • Clinical Trials: What You Should Know Before Volunteering to be a Research Subject.
    • The decision to participate in a clinical trial of the safety and effectiveness of a new treatment is a highly personal one. Understanding how and why clinical trials are conducted is an essential step in making the decision. In this ......
  • Clinical trial registration.
    • I have some concerns about medical research ("Pushing for Clinical Trial Registration," Oct. 1, 2004, p. 1). With regard to selective reporting of clinical trials, it seems clear to me that to make the best decisions, all the data are ......
  • VIOQUEST INITIATES CLINICAL TRIAL FOR AKT THERAPEUTIC.
    • VioQuest Pharmaceuticals (OTCBB:VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P). This trial is being conducted in ......
  • India No. 2 destination for clinical trial outsourcing.
    • BANGALORE: A recent global study conducted by consulting firm AT Kearney says that India is the second most preferred destination for outsourcing of clinical trials for the pharma industry. China tops the list and Russia figures as a close third....
  • Expert advice on conducting an office-based clinical trial.
    • MIAMI BEACH -- Conducting a clinical trial in your office can be professionally satisfying and financially rewarding, according to a presentation by Dr. David M. Pariser at a symposium sponsored by the Florida Society of Dermatology and Dermatologic Surgery. Formerly ......
  • CYLENE INITIATES PHASE I CLINICAL TRIAL FOR CX-3543.
    • Cylene Pharmaceuticals, San Diego, Calif., an oncology drug discovery and development company, has initiated a Phase I clinical trial for CX-3543, its lead candidate for the treatment of multiple cancers. CX-3543 is a first-in-class small molecule with a novel mechanism ......
  • 'Lupin can conduct anti-psoriasis clinical trials'.
    • MUMBAI: Lupin has received approval from the Drugs Controller General (India) to conduct a combined phase-IIb/III clinical trial for its herbal anti-psoriasis compound. The botanical drug product is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis....
  • EXELIXIS INITIATES PHASE I CLINICAL TRIAL FOR ANTICANCER XL820.
    • Exelixis, Inc. (NASDAQ:EXEL), South San Francisco, has initiated a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of XL820, a novel, orally administered, small molecule anticancer compound. XL820 is a Spectrum Selective Kinase Inhibitor (SSKITM) that ......

Related Topics

Subject: 
Industries: 
Site Map | Contact Us | About Us

Copyright © 1999 - 2009 AllBusiness.com Inc. All rights Reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Copyright 2009 The Gale Group, Inc. All rights reserved.
© COPYRIGHT 2008 M2 Communications Ltd.


You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.

Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Online Business Database
Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists | AllBusiness.com